Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYMS101
- Development stage
- Unknown
- Lead developer
- FibroBiologics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CYMS101 is a clinical-stage, allogeneic fibroblast-based cell therapy developed by FibroBiologics for the treatment of multiple sclerosis (MS). Fibroblasts are versatile, non-stem cells harvested from skin tissue that exhibit potent immunomodulatory and regenerative capabilities similar to mesenchymal stem cells (MSCs), but with greater ease of expansion and scalability. The therapy is designed to modulate the pathological immune response in MS and promote the repair of damaged myelin, potentially slowing disease progression. It is currently being evaluated in Phase 1 clinical trials.
- Other names
- CYMS101CYMS-101CYMS 101
Beyond the preview
Go deeper on CYMS101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYMS101.